RT journal article T1 Intravitreal Bevacizumab for Retinopathy of Prematurity: Another Hit to the Immature Lung? A1 Alonso-Ojembarrena, Almudena A1 Oulego‑Erróz, Ignacio K1 Retinopathy of prematurity (ROP) K1 Bevacizumab K1 Retinopathy of Prematurity AB Laser photocoagulation has been the standard oftreatment of ROP for many years. However, since itsintroduction in 2007, the use of intravitreal injection ofanti-VEGF agents has been incorporated to ROPmanagement. Several trials have shown that anti-VEGFdrugs (bevacizumab, ranibizumab) may be superior tolaser photocoagulation for type I ROP (zone I [any stagewith plus disease] or zone I-stage 3 without plusdisease) PB Elsevier SN 0012-3692 YR 2022 FD 2022-12-06 LK http://hdl.handle.net/10498/29411 UL http://hdl.handle.net/10498/29411 LA eng DS Repositorio Institucional de la Universidad de Cádiz RD 16-nov-2026